Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CEST
2023年9月22日 - 12:55AM
Mithra to Hold Investor Call on H1 2023 Financial Results on
September 26 at 14:00 CEST
Mithra to Hold Investor
Call on H1 2023 Financial Results on September 26
at 14:00 CEST
Liege,
Belgium,
September 21,
2023
– 5:45 pm
CEST – Mithra
(Euronext Brussels: MITRA), a company dedicated to Women’s Health,
today announces it will host a conference call to present its
financial results for the six-month period ended on June 30,
2023.
The call will take place on September 26 at
14:00 CEST and will be held in English. Participants can
attend/register for the live webcast of the call here. A replay of
the webcast will be available on the Investor Relations section of
the Mithra website shortly after the close of the call.
For more information, please
contact:
Mithra Pharmaceuticals SADavid Horn SolomonChief
Executive Officerinvestorrelations@mithra.com |
|
Investor &
media relationsChris MaggosCohesion
Bureauchris.maggos@cohesionbureau.com+41 79 367 6254 |
About
Mithra
Mithra Pharmaceuticals SA (Euronext: MITRA) is a
Belgian biopharmaceutical company dedicated to transforming Women’s
Health by offering new choices through innovation, with a
particular focus on contraception and menopause. Mithra’s goal is
to develop products offering better efficacy, safety and
convenience, meeting women’s needs throughout their life span.
Mithra explores the potential of the unique native estrogen
estetrol in a wide range of applications in women health and
beyond. After having successfully launched the first estetrol-based
product in 2021, the contraceptive pill Estelle®, Mithra is now
focusing on its second product Donesta®, the next-generation
hormone therapy. Mithra also offers partners a complete spectrum of
solutions from early drug development, clinical batches and
commercial manufacturing of complex polymeric products (vaginal
ring, implants) and complex liquid injectables and biologicals
(vials, pre-filled syringes or cartridges) at its technological
platform Mithra CDMO. Active in more than 100 countries around the
world, is headquartered in Liège, Belgium. www.mithra.com
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
Subscribe to our mailing list on investors.mithra.com to receive
our press releases by email or follow us on our social media
:Linkedin • Twitter • Facebook |
Mithra Pharmaceuticals (EU:MITRA)
過去 株価チャート
から 12 2024 まで 1 2025
Mithra Pharmaceuticals (EU:MITRA)
過去 株価チャート
から 1 2024 まで 1 2025